Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.

<p>Jnana Therapeutics specializes in discovering and developing medicines to expand the universe of therapeutic impact. By combining deep drug discovery, development expertise and their proprietary technology, Jnana is unlocking highly validated but previously undruggable targets. Drug discovery involves use of Jnana’s chemoproteomic platform, Reactive Affinity Probe Interaction Discovery (RAPID), a proprietary ligand platform to identify small molecule binders irrespective of the target. The unbiased approach of RAPID allows challenging targets, such as transcription factors and helicases, to be investigated. By using their RAPID platform, Jnana is developing a pipeline targeting many rare genetic diseases, immune-mediated diseases and oncology.  </p>


Jnana Therapeutics

Scientist I/II, Early Discovery Biology

Don't see a perfect job? Apply opportunistically.

Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU - Business Wire

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform - Business Wire

 SLC6A19 inhibitors disclosed in Jnana Therapeutics patent 

Exclusive: Jnana says pivotal trial of PKU pill could begin next year after promising results from a smaller study - Endpoints News

Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited Metabolic Disorders Annual Meeting - Business Wire


								Sep 04, 2024
								Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
							

Jnana closes $50 million financing to advance lead PKU program - The Pharma Letter

 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION 

Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform - PR Newswire

This year marks the 10th anniversary of the International Day of Women + Girls in Science. 

We recognize and celebrate the contributions of women scientists, including our Jnana team members, who are driving therapeutic innovations. 

#WomeninScience #WomeninSTEM   

Otsuka to buy Jnana in deal that may exceed $1 billion - The Pharma Letter

www.jnanatx.com

Jnana Therapeutics Promotes Joel Barrish, Ph.D., to President - citybiz

Otsuka Pharmaceutical To Acquire Jnana Therapeutics For $800M - Contract Pharma

Thanks to Dean Brown, Ph.D., and Heike Wobst, Ph.D., for their leadership at this week’s Drug Discovery Chemistry conference.

Dean is facilitating a breakout discussion as part of the Fragment-Based Drug Discovery Best Practices & Innovations session. Heike is chair of the Degrader Approaches for KRAS session.

More about the conference here: https://lnkd.in/gkhkep5 #DrugDiscoveryChemistry Only registered participants of the Drug Discovery Chemistry Conference are eligible to attend as determined by the event organizer. Jnana has no control over registration, or the fees associated.
April 2025 01US25EUP0016

At #BIO2024 this week? Caroline Stark Beer, Chief Business Officer at Jnana, will be speaking on a panel titled “Exploring Deal-Making Options for Your Portfolio of Assets.”  
 
The session will examine and discuss business development opportunities across a range of deal structures. Under Caroline’s leadership, Jnana has entered into two strategic collaborations with Roche.  
 
More about the BIO panel here: https://bit.ly/4bKgZPv #biopharma #collaboration  

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases - PR Newswire

 Crystalline forms of a piperidine inhibitor of slc6a19 function 

 Treating pku with correctors of mammalian slc6a19 function 

FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018 - Business Wire

Boston biotech Jnana raises $107 million and strikes second collaboration with Roche - The Boston Globe

We’re excited to share the recipients of our 2024 awards, recognizing team members who have gone above and beyond.

Congrats to our entire team on a year of many achievements at Jnana!

[Pictured L to R: Susan Cantin, Josh Zweig, Long Nguyen, David Rogers, CPA, Devin Diedrich, Tamanna Asarpota, Frank Wu; not pictured recipients: Alex Fitz, Lea Rosskamp]

Jnana Therapeutics announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical Co.

By bringing together the strength of Jnana’s RAPID platform with Otsuka’s global capabilities and resources, the proposed transaction will further enable the development of novel therapies for under-addressed diseases, including JNT-517 for PKU.

Upon completion of the acquisition later this year, Jnana will operate as a wholly owned subsidiary of Otsuka in Boston and continue its research and development.

Read more: https://bit.ly/4ftndW9 #biotechnology #biopharma #acquisition

 Jnana Therapeutics Announces Appointment of John Throup, Ph.D. as Senior Vice President, Head of Development 

Otsuka to buy Boston chemoproteomics biotech for up to $1.1B - BioWorld Online

Jnana reports data from trial of JNT-517 for phenylketonuria - Clinical Trials Arena



		
			
				May 10, 2024
							
		

		
			Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
		

	

Otsuka Pharmaceutical’s Acquisition of Jnana Therapeutics - Global Legal Chronicle



		
			
				Sep 04, 2024
							
		

		
			Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
		

	

Jnana Therapeutics discovers new SLC6A19 inhibitors - BioWorld MedTech

Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn - PMLiVE



		
			
				Sep 06, 2023
							
		

		
			Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
		

	

Otsuka Agrees to Acquire Jnana Therapeutics - Contract Pharma

 Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics 

 Roche partners with Jnana on SLC transporters 

Belharra Therapeutics sticks with lead programs, trims workforce by 40% - Endpoints News

 Treating pku with spiro-substituted and other piperidine inhibitors of slc6a19 … 

Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug - MedCity News

Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics - ET HealthWorld

 Jnana Therapeutics Announces Promotion of Joel Barrish, Ph.D., to President and Chief Scientific Officer 

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases - Business Wire

Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates - Business Wire

BridGene nets another Takeda deal amid plans to raise more funding and go public - Endpoints News

 Jnana Therapeutics lures Janssen exec to be its new CMO and head of R&D 

 Jnana Therapeutics’ Post 

Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities - BioSpace

Jnana nets $50M to push newly unveiled PKU program ...

We’re excited to share the story of the discovery and early clinical development of JNT-517, our oral small molecule drug candidate being evaluated in PKU, in the peer-reviewed journal JCI Insight. 

Find the publication here: https://bit.ly/3D2qDR4.

Thanks to our team for their work on this publication!

 Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function 

Platform, PKU asset drive Otsuka’s $800M takeout of Jnana - BioCentury

Roche, Jnana take aim at metabolite transporters in $40M ...

Our team joined the National PKU Alliance’s Move your Pheet for PKU challenge last month in honor of National PKU Awareness Month. 

We’ll help support the PKU community by strolling around the Seaport anytime! #PKU #raredisease


Otsuka pays $800M for Jnana and its clinical-stage PKU drug

 Jnana Therapeutics describes new SLC6A19 inhibitors 

Jnana President Joanne Kotz to take on CEO role - Fierce Biotech

Neurocrine, Jnana team up to discover CNS drugs - Fierce Biotech

Nirogy Therapeutics emerges with $16.5M to target metabolite transporters - Fierce Biotech

 Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche 

Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche - GlobeNewswire

New SLC6A19 inhibitors divulged in Jnana Therapeutics patents - BioWorld Online

Deals in brief: Slice snags USD 17.5 million, Dubai-based National Pulse invests in Aleta Planet, Japan’s Otsuka Pharma to acquire Jnana Therapeutics, and more - KrASIA

Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - GlobeNewswire

 Bicyclic heteroaryl-containing piperidine inhibitors of slc6a19 function 

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash - Endpoints News

Latham & Watkins Advises Jnana Therapeutics in Acquisition by Otsuka Pharmaceutical - Latham & Watkins LLP

Jnana Therapeutics to Participate in Upcoming Investor Conferences - Business Wire

Jnana Therapeutics Announces Positive Clinical Proof of - GlobeNewswire

Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria - PR Newswire

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership - Labiotech.eu

Skadden, Latham act on $1.1 bln Japan outbound pharma deal - Legal Business Online

Phenylketonuria Market to Exhibit Significant Growth, - GlobeNewswire

Japan's Otsuka Pharma acquires American biotech startup Jnana Therapeutics for $1.1 B - BSA bureau

Otsuka buys Jnana and PKU drug in $1.1bn deal - pharmaphorum

PKU is a rare, inherited metabolic disease that can cause progressive and severe neurological impairment and neuropsychological complications. There’s a critical need for a safe and efficacious treatment for individuals with PKU. This year, International PKU Day focuses on raising awareness about the lives of adults with PKU. 

Find out more at: https://www.espku.org/ #PKU #adultPKUawareness #PKUDAY2024 

Jnana tops up with $107M series C, $2B Roche deal ...

As we close PKU Awareness Month, we are reminded that there remains a tremendous need for new treatments for phenylketonuria (PKU). Jnana is committed to advancing clinical research to meet the critical needs of PKU patients.

May 2025 01US25EUC0241


Phenylketonuria (PKU) is one of many rare genetic diseases that are diagnosed in childhood. There continues to be a critical need for a safe and efficacious treatment for PKU, which can cause progressive and severe neurological impairment and neuropsychological complications. 

At Jnana, we are currently advancing JNT-517 as a potential first-in-class oral treatment for PKU. Learn more about our clinical studies: https://bit.ly/41h4dUQ #RareDiseaseDay


Maze Therapeutics discovers new SLC6A19 inhibitors - BioWorld Online



		
			
				Feb 01, 2024
							
		

		
			Jnana says pivotal trial of PKU pill could begin next year after promising results from a smaller study
		

	

Jnana closes $107M series C round, banks $50M up front in second discovery Roche pact - BioWorld MedTech

Jnana Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Attending #SSIEM24? Join us on Thursday, Sept 5, for a symposium on the potential for SLC6A19 inhibition as a treatment approach for PKU and other amino acid disorders. 

We’re looking forward to hearing from presenters Cary O. Harding, MD, Nicola Longo, MD, Ania C. Munta, MD, and John Throup, PhD. 

Details here: https://bit.ly/3yTChfz #SSIEM #clinicaltrials #PKU


								Sep 23, 2024
								Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
							

Jnana reports topline data from Phase Ia trial of PKU therapy - Clinical Trials Arena

Startup Jnana raises $50M to tackle elusive membrane protein targets - Fierce Biotech



		
			
				Aug 01, 2024
							
		

		
			Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
		

	

Neurocrine, Jnana team up to discover CNS drugs

SLC6A19 inhibitors disclosed in Jnana Therapeutics patent - BioWorld Online

 Roche backs Jnana quest to drug SLC transporters with $40M down payment 

Investors Launch Biotech Startup Jnana Therapeutics With $50 Million - WSJ

 Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 

 Piperidine inhibitor of slc6a19 function 


								Aug 01, 2024
								Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
							

 Jnana closes $50M series B round, picks PKU as lead indication 

Roche backs Jnana quest to drug SLC transporters with $40M down payment - BioWorld MedTech

Otsuka pays $800M for Jnana Therapeutics and its clinical-stage PKU drug - Fierce Biotech

We are proud to announce that Jnana Therapeutics is now part of Otsuka Pharmaceutical Co., Ltd. Jnana will continue to be based in Boston and operate as a direct subsidiary of Otsuka America, Inc. 

We look forward to continuing our mission to develop small molecules against challenging-to-drug targets for under-addressed diseases and advancing JNT-517 into a pivotal Phase 3 study for PKU in early 2025. Read more: https://bit.ly/3ZD6b2q
 
#acquisition #pharmaceuticals #biotechnology 

Jnana Therapeutics tries to take on an untapped class of proteins - Chemical & Engineering News

Today, we presented clinically meaningful, statistically significant results from the second-dose cohort of the Phase 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU) at the Society for the Study of Inborn Errors of Metabolism 2024 Annual Symposium.

Based on these positive results, we plan to advance JNT-517 directly into a pivotal Phase 3 study in early 2025. Read more: https://bit.ly/47fmynI

#SSIEM24 #clinicaltrials #raredisease #PKU


Jnana Therapeutics

Business:

Drug notes:

About: